New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 29, 2012
13:51 EDTARNA, VVUS, OREXVIVUS drug's CV profile viewed positively by FDA, says Rodman & Renshaw
After attending an FDA panel hearing focused on the effects of anti-obesity drugs on cardiovascular systems, Rodman & Renshaw believes that the FDA and the panel are comfortable with the cardiovascular profile of VIVUS' drug, Qnexa. The firm indicates that it doesn't expect the agency to require additional cardiovascular tests before Qnexa is approved, and it reiterates an Outperform rating on VIVUS.
News For VVUS;ARNA;OREX From The Last 14 Days
Check below for free stories on VVUS;ARNA;OREX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
10:31 EDTOREXHigh option volume stocks:
High option volume stocks: EZPW LCI STLD SIAL FL OREX CROX NIHD EXTR BBT
08:11 EDTARNAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
July 16, 2014
09:37 EDTARNAActive equity options trading on open
Subscribe for More Information
July 15, 2014
16:34 EDTARNAArena Pharmaceuticals granted patent for Cannabinoid Receptor Modulators
Arena Pharmaceuticals announced that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators," by the U.S. Patent and Trademark Office for APD371, an agonist of the cannabinoid receptor 2. Arena is exploring several potential indications for APD371, including chronic pain, and is currently conducting a Phase 1 single-ascending dose trial.
10:40 EDTARNAArena Pharmaceuticals receives USPTO patent for cannabinoid receptor modulators
Reference Link
July 11, 2014
11:31 EDTOREXOptions with increasing implied volatility
Options with increasing implied volatility: INO AEGR UBNT INVN WTW OREX GNC CREE SD SAN
July 10, 2014
08:08 EDTARNAArena Pharmaceuticals reports that Eisai increases sales force for Belviq
Arena Pharmaceuticals reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for Belviq by 50% to approximately 600. Eisai expects this expansion of the sales force will enable them to increase their reach to approximately 92,000 physicians in the U.S.
July 9, 2014
11:51 EDTOREXOptions with increasing implied volatility:
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use